Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial

Martin Pecherstorfer, Saul Rivkin, Jean-Jacques Body, Ingo Diel, Bengt Bergström

Research output: Journal article (peer-reviewed)Journal article

38 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science